000			01775 a2200529 4500
005			20250515072853.0
264		0	_c20070823
008			200708s 0 0 eng d
022			_a0269-9370
024	7		_a10.1097/QAD.0b013e3281fc9320 _2doi
040			_aNLM _beng _cNLM
100	1		_aCrane, Heidi M
245	0	0	_aAmprenavir and didanosine are associated with declining kidney function among patients receiving tenofovir. _h[electronic resource]
260			_bAIDS (London, England) _cJul 2007
300			_a1431-9 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, N.I.H., Extramural
650	0	4	_aAdenine _xanalogs & derivatives
650	0	4	_aAdult
650	0	4	_aAge Factors
650	0	4	_aAnalysis of Variance
650	0	4	_aAnti-HIV Agents _xadverse effects
650	0	4	_aAntiretroviral Therapy, Highly Active
650	0	4	_aBody Weight
650	0	4	_aCarbamates _xadverse effects
650	0	4	_aCreatinine _xurine
650	0	4	_aDidanosine _xadverse effects
650	0	4	_aDrug Interactions
650	0	4	_aFemale
650	0	4	_aFurans
650	0	4	_aGlomerular Filtration Rate _xdrug effects
650	0	4	_aHIV Infections _xdrug therapy
650	0	4	_aHIV-1
650	0	4	_aHumans
650	0	4	_aKidney _xdrug effects
650	0	4	_aLinear Models
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aOrganophosphonates _xtherapeutic use
650	0	4	_aSulfonamides _xadverse effects
650	0	4	_aTenofovir
650	0	4	_aTime Factors
700	1		_aKestenbaum, Bryan
700	1		_aHarrington, Robert D
700	1		_aKitahata, Mari M
773	0		_tAIDS (London, England) _gvol. 21 _gno. 11 _gp. 1431-9
856	4	0	_uhttps://doi.org/10.1097/QAD.0b013e3281fc9320 _zAvailable from publisher's website
999			_c17126300 _d17126300